ArticleTheranostics2018
Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Endogenous targeting lipid nanoparticles for systemic mRNA delivery to lung cancer tumors.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics.Journal of translational medicine · 2026Review
- Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functions.Molecular and cellular biochemistry · 2025Review
- Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions.Frontiers in pharmacology · 2025Review
- Glutathione-Responsive Methotrexate Polymersomes for Potential Management of Ectopic Pregnancy.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance.Biology · 2024Review
- mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.Journal of biomedical science · 2023Review
- Circular RNA vaccine in disease prevention and treatment.Signal transduction and targeted therapy · 2023Review
- Nanoparticles systemically biodistribute to regenerating skeletal muscle in DMD.Journal of nanobiotechnology · 2023Article
- Novel Nanoparticle-Based Treatment and Imaging Modalities.Pharmaceutics · 2023Article
- mRNA-based modalities for infectious disease management.Nano research · 2023Review
- Poly(aspartic acid)-Based Polymeric Nanoparticle for Local and Systemic mRNA Delivery.Molecular pharmaceutics · 2022Article
- mRNA cancer vaccines: Advances, trends and challenges.Acta pharmaceutica Sinica. B · 2022Review
- mRNA-based therapeutics: powerful and versatile tools to combat diseases.Signal transduction and targeted therapy · 2022Review
- mRNA-based therapeutics: powerful and versatile tools to combat diseases.Signal transduction and targeted therapy · 2022Review
- New intranasal and injectable gene therapy for healthy life extension.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Synthetic modified messenger RNA for therapeutic applications.Acta biomaterialia · 2021Review
- Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.Small (Weinheim an der Bergstrasse, Germany) · 2021Review
- From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.Frontiers in immunology · 2021Review
- mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes. There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements. Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.